Faculty of Medicine and Psychology, Digestive and Liver Disease Unit, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy.
J Clin Gastroenterol. 2012 Oct;46 Suppl:S46-51. doi: 10.1097/MCG.0b013e3182652096.
The small intestine is one of the distant organs that become damaged during severe acute pancreatitis, due to microcirculation disturbance associated with loss of fluids in the "third space," hypovolemia, splanchnic vasoconstriction, and finally an ischemia-reperfusion injury. In this scenario, the gut acts as the starter for severe systemic complications, as the failure of the intestinal barrier is associated with translocation of bacteria and inflammatory and toxic products produced in the intestinal wall, which can be responsible for sepsis and infection of the necrotic pancreas and for systemic inflammatory response. Therefore, one of the main goals of treatment in the early phases of severe acute pancreatitis should be to maintain the integrity of the gut barrier in the small intestine. These strategies include appropriate fluid resuscitation to limit the damage due to the relative hypovolemia and early enteral feeding. The role of intravenous antibiotics to prevent infection of the pancreatic necrosis is controversial and the role of probiotics, which seemed a promising tool in vitro and in early clinical trials, needs to be further investigated to better understand the effects of the single specific strains at various doses and timing before designing new clinical trials.
小肠是在重症急性胰腺炎期间受损的远隔器官之一,这是由于与“第三间隙”液体丢失相关的微循环障碍、血容量不足、内脏血管收缩,最终发生缺血再灌注损伤。在这种情况下,肠道是严重全身并发症的启动因素,因为肠道屏障的衰竭与肠道壁内细菌和炎症及毒性产物的易位有关,这些产物可导致脓毒症和胰腺坏死感染,并引发全身炎症反应。因此,重症急性胰腺炎早期治疗的主要目标之一应该是维持小肠的肠道屏障完整性。这些策略包括适当的液体复苏,以限制相对血容量不足和早期肠内喂养造成的损害。静脉内使用抗生素预防胰腺坏死感染的作用存在争议,而益生菌的作用在体外和早期临床试验中似乎是一种很有前途的工具,需要进一步研究,以更好地了解在设计新的临床试验之前,不同剂量和时间下单一特定菌株的作用。